Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANX-514 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ANX-514 |
| 2 | ACTIVE_COMPARATOR | Taxotere |
| Name | Type | Description |
|---|---|---|
| ANX-514 | DRUG | 75 mg/m\^2 |
| docetaxel | DRUG | 75 mg/m\^2 |
Inclusion Criteria: * Over 18 years old. * Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment. * E...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ANX-514 is an investigational small molecule being studied for the treatment of advanced cancer. It is a docetaxel injectable emulsion formulation. A Phase 1 bioequivalence study evaluated ANX-514 in patients with advanced cancer to compare it with a reference product. The study has been completed.
ANX-514 is being developed by Savara, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SVRA. The company is conducting clinical development of this investigational oncology drug.
ANX-514 is in Phase 1 clinical development. A single Phase 1 study, NCT00664170, has been completed. The drug is investigational and has not been approved by regulatory authorities. It remains in early-stage clinical development for advanced cancer.
ANX-514 has one completed clinical trial, NCT00664170, titled 'A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer.' This Phase 1 study enrolled 39 participants and was conducted in the United States, Argentina, and Estonia.
ANX-514 is a formulation of docetaxel, specifically an injectable emulsion. The clinical trial NCT00664170 was designed as a bioequivalence study comparing ANX-514 to a reference docetaxel product. ANX-514 is being developed as an alternative formulation of docetaxel for advanced cancer.